Pfizer Keeping the ADC Faith: Potential $635M CytomX Deal
CytomX Therapeutics Inc.'s oncology deal with Pfizer Inc. to develop Probody-drug conjugates gives the pharma giant rights to develop selected candidates in exchange for a potential $25 million up front, as well as $610 million if regulatory and sales milestones are met.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter